Washington University School of Medicine in St. Louis | Strategic Alliance Partners

Latest from Washington University School of Medicine in St. Louis


Visualizing Cancer Cells With the Help of High-tech Eyewear

February 17, 2014

High-tech eyewear could soon help surgeons remove tumors from patients with breast cancer or melanoma by allowing them to see the margins of tumors more accurately when a dye is used to fluoresce a tumor's borders.

FALCON Trial Compares Two Types of Endocrine Therapy

December 19, 2013

The question of whether fulvestrant (Faslodex) should be moved forward in the treatment timeline for postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer is being evaluated in an international, randomized phase III trial.

PCPT Trial Helps Confirm Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention

December 17, 2013

Two years after the FDA denied a request to expand the indication of finasteride and other 5α-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.

Academic Medical Oncologists Complement Role of Community Oncologists in Sarcoma Treatment

October 24, 2013

One of the privileges of working in an academic medical center is the luxury of being able to subspecialize in the treatment of sarcoma. Nationwide, there may be 40 to 50 medical oncologists who focus on the treatment of adult soft tissue and bone sarcoma.

National Cancer Institute Awards Leukemia Reseachers at Siteman $26 Million

October 07, 2013

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

Dr. Aft on Bisphosphonates for Breast Cancer

September 18, 2013

Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

Dr. Matthew J. Ellis on the Future of TCGA

August 27, 2013

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer

February 05, 2013

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

x